572 related articles for article (PubMed ID: 30400220)
1. Innovative Immunization Strategies for Antivenom Development.
Bermúdez-Méndez E; Fuglsang-Madsen A; Føns S; Lomonte B; Gutiérrez JM; Laustsen AH
Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30400220
[TBL] [Abstract][Full Text] [Related]
2. Envenoming and antivenom use in Australia.
White J
Toxicon; 1998 Nov; 36(11):1483-92. PubMed ID: 9792162
[TBL] [Abstract][Full Text] [Related]
3. Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
Alomran N; Alsolaiss J; Albulescu LO; Crittenden E; Harrison RA; Ainsworth S; Casewell NR
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009659. PubMed ID: 34407084
[TBL] [Abstract][Full Text] [Related]
4. Antivenoms for the treatment of snakebite envenomings: the road ahead.
Gutiérrez JM; León G; Burnouf T
Biologicals; 2011 May; 39(3):129-42. PubMed ID: 21429763
[TBL] [Abstract][Full Text] [Related]
5. Biotechnological Trends in Spider and Scorpion Antivenom Development.
Laustsen AH; Solà M; Jappe EC; Oscoz S; Lauridsen LP; Engmark M
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27455327
[TBL] [Abstract][Full Text] [Related]
6. Antivenom efficacy or effectiveness: the Australian experience.
Isbister GK
Toxicology; 2010 Feb; 268(3):148-54. PubMed ID: 19782716
[TBL] [Abstract][Full Text] [Related]
7. A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms.
Ratanabanangkoon K
Front Immunol; 2021; 12():668328. PubMed ID: 33968072
[TBL] [Abstract][Full Text] [Related]
8. Engineering and design considerations for next-generation snakebite antivenoms.
Knudsen C; Ledsgaard L; Dehli RI; Ahmadi S; Sørensen CV; Laustsen AH
Toxicon; 2019 Sep; 167():67-75. PubMed ID: 31173790
[TBL] [Abstract][Full Text] [Related]
9. The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment.
Machado Marinho AC; Chapeaurouge A; Dutra BM; Quintela BCSF; Pereira SS; Fernandes CFC
Drug Discov Today; 2024 May; 29(5):103967. PubMed ID: 38555033
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Utility of Recombinant Snake Venom Serine Protease Toxins as Immunogens for Generating Experimental Snakebite Antivenoms.
Alomran N; Blundell P; Alsolaiss J; Crittenden E; Ainsworth S; Dawson CA; Edge RJ; Hall SR; Harrison RA; Wilkinson MC; Menzies SK; Casewell NR
Toxins (Basel); 2022 Jun; 14(7):. PubMed ID: 35878181
[TBL] [Abstract][Full Text] [Related]
11. Cross neutralization of coral snake venoms by commercial Australian snake antivenoms.
Ramos HR; Vassão RC; de Roodt AR; Santos E Silva EC; Mirtschin P; Ho PL; Spencer PJ
Clin Toxicol (Phila); 2017 Jan; 55(1):33-39. PubMed ID: 27595162
[TBL] [Abstract][Full Text] [Related]
12. Snake venomics and antivenomics: Proteomic tools in the design and control of antivenoms for the treatment of snakebite envenoming.
Gutiérrez JM; Lomonte B; León G; Alape-Girón A; Flores-Díaz M; Sanz L; Angulo Y; Calvete JJ
J Proteomics; 2009 Mar; 72(2):165-82. PubMed ID: 19344652
[TBL] [Abstract][Full Text] [Related]
13. An interactive database for the investigation of high-density peptide microarray guided interaction patterns and antivenom cross-reactivity.
Krause KE; Jenkins TP; Skaarup C; Engmark M; Casewell NR; Ainsworth S; Lomonte B; Fernández J; Gutiérrez JM; Lund O; Laustsen AH
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008366. PubMed ID: 32579606
[TBL] [Abstract][Full Text] [Related]
14. Terrestrial venomous animals, the envenomings they cause, and treatment perspectives in the Middle East and North Africa.
Jenkins TP; Ahmadi S; Bittenbinder MA; Stewart TK; Akgun DE; Hale M; Nasrabadi NN; Wolff DS; Vonk FJ; Kool J; Laustsen AH
PLoS Negl Trop Dis; 2021 Dec; 15(12):e0009880. PubMed ID: 34855751
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa.
Harrison RA; Oluoch GO; Ainsworth S; Alsolaiss J; Bolton F; Arias AS; Gutiérrez JM; Rowley P; Kalya S; Ozwara H; Casewell NR
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005969. PubMed ID: 29045429
[TBL] [Abstract][Full Text] [Related]
16. Snake antivenom: Challenges and alternate approaches.
Alangode A; Rajan K; Nair BG
Biochem Pharmacol; 2020 Nov; 181():114135. PubMed ID: 32628928
[TBL] [Abstract][Full Text] [Related]
17. Antivenom for European Vipera species envenoming.
Lamb T; de Haro L; Lonati D; Brvar M; Eddleston M
Clin Toxicol (Phila); 2017 Jul; 55(6):557-568. PubMed ID: 28349771
[TBL] [Abstract][Full Text] [Related]
18. Development of Equine IgG Antivenoms against Major Snake Groups in Mozambique.
Guidolin FR; Caricati CP; Marcelino JR; da Silva WD
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004325. PubMed ID: 26730709
[TBL] [Abstract][Full Text] [Related]
19. From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy.
Laustsen AH; Engmark M; Milbo C; Johannesen J; Lomonte B; Gutiérrez JM; Lohse B
Curr Pharm Des; 2016; 22(34):5270-5293. PubMed ID: 27339430
[TBL] [Abstract][Full Text] [Related]
20. Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims.
Kini RM; Sidhu SS; Laustsen AH
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
